Anthropic has added Vas Narasimhan — physician-scientist and CEO of pharma giant Novartis — to its Board of Directors, appointed by the company's Long-Term Benefit Trust. The move is notable less for the name and more for what it signals structurally: Trust-appointed directors now hold a majority of Anthropic's board seats.
What's new
Narasimhan joins existing board members Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell. He was appointed by the Long-Term Benefit Trust — an independent body whose members hold no financial stake in Anthropic — which exists specifically to keep the company's governance balanced between investor returns and its public benefit mission. This is the mechanism built into Anthropic's Public Benefit Corporation structure, and with this appointment, the Trust's picks now outnumber stockholder-elected directors on the board.
Why it matters
Narasimhan's background is the practical argument here: he oversaw the development and approval of more than 35 novel medicines at Novartis, navigating one of the most heavily regulated industries on the planet. Anthropic is explicitly framing this as importing hard-won expertise in getting powerful technology deployed safely and at scale — not just a healthcare industry credential. The Trust's own framing underscores the governance angle: they want directors who will hold the line on Anthropic's public benefit mission as the company grows and commercial pressure increases.
What to watch
The Trust-majority board structure is the detail worth tracking long-term. Anthropic has built its governance around the premise that a purely investor-driven board creates misaligned incentives for a frontier AI lab. Whether that structure holds as the company scales — and whether Trust-appointed directors with backgrounds like Narasimhan's actually influence technical and safety decisions in practice — is the real question this appointment raises.